The test, dubbed Colvera, helps to determine the presence or absence of two altered genes associated with CRC.

The test evaluates methylation, a genetic change associated with cancer development in circulating tumor DNA (ctDNA), the fragments of genetic material that leak from a tumor into the bloodstream.

Clinical Genomics said the test is not intended to distinguish the risk of recurrence in colorectal cancer patients, but rather to identify the presence of disease at the time of testing.

It can be administered along with other CRC surveillance tests such as CEA, as it only requires a peripheral blood sample.

The company will perform Colvera test at CLIA-registered laboratory in Bridgewater, New Jersey. Quest Diagnostics will offer specimen collection and logistics services for test orders.

Through its subsidiary Enterix, Clinical Genomics provides CRC screening InSure FIT fecal immunochemical test that detects blood in the stool.

Clinical Genomics president and CEO Dr Lawrence LaPointe said: "Colorectal cancer outcomes improve with early detection, but many recurrence monitoring tests fail to detect disease at a point when clinical intervention has the best chance to be effective.

"Colvera is a new test that can aid in the identification of molecular changes associated with cancer development. Colvera is intended to provide physicians with actionable information that can trigger further clinical assessment, which may lead to improved outcomes."